Sofgen Pharma

Sofgen Pharma EV/FCF

Delisted·Sep 1, 2026

The EV/FCF (Enterprise Value to Free Cash Flow) of Sofgen Pharma (PROCF) as of Oct 16, 2026 is 18.83. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 15.82 — a change of 19.04% (higher).

EV/FCF

18.83

YoY

19.04%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Sofgen Pharma is 2024 18.83 . EV/FCF (Enterprise Value to Free Cash Flow) of Sofgen Pharma was 2023 15.82 . It decreases by 19.04% higher compared to the previous year.

The Sofgen Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
23.73 USD
Jan 1, 2021
122.96 USD
Jan 1, 2022
-63.66 USD
Jan 1, 2023
15.82 USD
Jan 1, 2024
18.83 USD
The Sofgen Pharma EV/FCF history
YEAREV/FCFYoY
18.83+19.04%
15.82-124.85%
-63.66-151.78%
122.96+418.14%
23.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Sofgen Pharma SA, listed under the ticker PROCF with ISIN LU2376511205, is a pharmaceutical company headquartered in Luxembourg. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Sofgen Pharma employs approximately 5,500 people and completed its initial public offering on December 9, 2019. The company's website is https://www.procapsgroup.com/. Sofgen Pharma SA develops, manufactures, and sells prescription drugs and products featuring unique combinations and pharmaceutical forms, alongside nutritional supplements such as omega-3 fish oils and high-potency clinical compounds. The company organizes its operations through five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics focuses on diabetes solutions. Farma Procaps is involved in formulating, manufacturing, and marketing branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to other pharmaceutical companies. Vital Care specializes in developing, manufacturing, and marketing consumer healthcare products. Clinical Specialties is dedicated to the development, manufacturing, and marketing of complex drugs. The company's business model emphasizes specialized pharmaceutical solutions and consumer health products, with a global operational footprint. Sofgen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sofgen Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Sofgen Pharma is 18.83 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Sofgen Pharma changed from 15.82 to 18.83, representing a 19.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Sofgen Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sofgen Pharma

All Key Metrics — Sofgen Pharma